Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

57.46USD
1:01pm EST
Price Change (% chg)

$0.25 (+0.44%)
Prev Close
$57.21
Open
$57.25
Day's High
$57.86
Day's Low
$57.25
Volume
1,060,650
Avg. Vol
2,987,241
52-wk High
$62.20
52-wk Low
$49.24

MRK.N

Chart for MRK.N

About

Merck & Co., Inc. is a health care company that offers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are comprised of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.34
Market Cap (Mil.): $163,098.50
Shares Outstanding (Mil.): 2,850.87
Dividend: 0.45
Yield (%): 3.15

Financials

  MRK.N Industry Sector
P/E (TTM): 31.36 38.19 38.61
EPS (TTM): 1.82 -- --
ROI: 6.72 19.00 18.27
ROE: 11.63 19.75 19.14
Search Stocks

CORRECTED-Connections between drug makers and educators abound

(Corrects second paragraph to say "scholarships funded by Merck, Zoetis, Cargill and others this year.")

23 Dec 2014

Exclusive: Can the blood of Ebola survivors create a cure?

CHICAGO - For months, Vanderbilt University researcher Dr. James Crowe has been desperately seeking access to the blood of U.S. Ebola survivors, hoping to extract the proteins that helped them overcome the deadly virus for use in new, potent drugs. | Video

22 Dec 2014

UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data

* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s

18 Dec 2014

Tetraphase's antibiotic succeeds late-stage trial, shares rise

- Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck & Co Inc's ertapenem in a late-stage study.

17 Dec 2014

UPDATE 2-Tetraphase's antibiotic succeeds late-stage trial, shares rise

* Shares rise 17.5 pct in extended trading (Adds details from conference call, analyst quotes)

17 Dec 2014

Tetraphase's antibiotic succeeds in late-stage trial

Dec 17 - Tetraphase Pharmaceuticals Inc said its antibiotic drug to treat complicated intra-abdominal infections was as effective as Merck & co Inc's ertapenem in a late-stage study.

17 Dec 2014

TRLPC: Merck looks for $8B bridge for Cubist acquisition

NEW YORK, Dec 15 - Merck & Co Inc is approaching banks about an $8 billion, 364-day bridge loan that will back the drugmaker's plans to acquire Cubist Pharmaceuticals Inc, sources told Thomson Reuters LPC.

15 Dec 2014

CORRECTED-India caps prices of 52 more "essential" drugs - pricing authority

(Corrects paragraph 4 to say Merck Ltd is a unit of Merck KGaA, not Merck & Co Inc)

12 Dec 2014

UPDATE 2-Ebola vaccine trial halted temporarily after joint pains -Geneva hospital

* Lausanne says safety data "satisfactory" in GSK vaccine trial (Adds statement on GSK Ebola vaccine, new paras 4-7)

11 Dec 2014

UPDATE 2-$300 mln pledged to buy Ebola vaccines as NewLink shot hits snag

* Further funding of up to $90 mln to help vaccine roll-out (Wraps stories on GAVI funding, NewLink vaccine trial, adds GAVI CEO comment)

11 Dec 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks